Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Managing liver disease

New Content ItemLiver disease is on the increase and is the fifth leading cause of death in the UK. The patients often show symptoms only at advanced stages when it is too late to cure.

Liver diseases can be caused by a multitude of factors, including genetic predisposition, infections and the environment, therefore requiring diverse and targeted treatment options. The increasing incidence of some hepatic conditions worldwide is due to lifestyle actions, including alcohol intake and drug treatments. Concurrently, numerous infections and disorders are challenging to treat, as the causes and progression of a number of illnesses are not yet well understood.

Among others, liver cancer, hepatitis, non-alcoholic fatty liver disease and end-stage liver disease are being studied extensively to improve our understanding of the mechanisms of disease progression, and guide treatment decisions in terms of therapy selection and timing. Much of today’s focus on liver diseases is also on the development of more effective targeted treatments.

This current article collection in BMC Medicine aims to feature the latest findings on the management of liver diseases, welcoming the submission of original research articles on the detection, management and new treatment techniques. Invited commentaries and reviews will also be included in the collection.

We would welcome direct submission of any original research within the collection scope – please submit directly to BMC Medicine stating in your cover letter that you are targeting the Managing liver disease collection. Alternatively please email your pre-submission queries to

  1. Non-alcoholic steatohepatitis (NASH) is among the leading causes of liver disease worldwide. It is increasingly recognized that the phenotype of NASH may involve a number of different pathways, of which each c...

    Authors: Zobair M. Younossi, Azza Karrar, Mariaelena Pierobon, Aybike Birerdinc, Maria Stepanova, Dinan Abdelatif, Zahra Younoszai, Thomas Jeffers, Sean Felix, Kianoush Jeiran, Alex Hodge, Weidong Zhou, Fanny Monge, Lakshmi Alaparthi, Vikas Chandhoke, Zachary D. Goodman…

    Citation: BMC Medicine 2018 16:170

    Content type: Research article

    Published on:

  2. Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide. It affects an estimated 20% of the general population, based on cohort studies of varying size and heterogeneous s...

    Authors: Myriam Alexander, A. Katrina Loomis, Jolyon Fairburn-Beech, Johan van der Lei, Talita Duarte-Salles, Daniel Prieto-Alhambra, David Ansell, Alessandro Pasqua, Francesco Lapi, Peter Rijnbeek, Mees Mosseveld, Paul Avillach, Peter Egger, Stuart Kendrick, Dawn M. Waterworth, Naveed Sattar…

    Citation: BMC Medicine 2018 16:130

    Content type: Research article

    Published on:

    The Commentary to this article has been published in BMC Medicine 2018 16:148

  3. The results of liver transplantation are excellent, with survival rates of over 90 and 80% at 1 and 5 years, respectively. The success of liver transplantation has led to an increase in the indications for liv...

    Authors: Didier Samuel and Audrey Coilly

    Citation: BMC Medicine 2018 16:113

    Content type: Opinion

    Published on:

  4. In real-world clinical practice, the acceptance of anticoagulation therapy in the management of portal vein thrombosis (PVT) in patients with cirrhosis is limited by the fear of an increased bleeding risk. Add...

    Authors: Xingshun Qi, Xiaozhong Guo, Eric M. Yoshida, Nahum Méndez-Sánchez, Valerio De Stefano, Frank Tacke, Andrea Mancuso, Yasuhiko Sugawara, Sien-Sing Yang, Rolf Teschke, Ankur Arora and Dominique-Charles Valla

    Citation: BMC Medicine 2018 16:83

    Content type: Minireview

    Published on:

  5. HCV treatment uptake has drastically increased in HIV-HCV coinfected patients in France since direct-acting antiviral (DAA) treatment approval, resulting in HCV cure in 63% of all HIV-HCV patients by the end o...

    Authors: Victor Virlogeux, Fabien Zoulim, Pascal Pugliese, Isabelle Poizot-Martin, Marc-Antoine Valantin, Lise Cuzin, Jacques Reynes, Eric Billaud, Thomas Huleux, Firouze Bani-Sadr, David Rey, Anne Frésard, Christine Jacomet, Claudine Duvivier, Antoine Cheret, Laurent Hustache-Mathieu…

    Citation: BMC Medicine 2017 15:217

    Content type: Research article

    Published on:

  6. Chronic hepatitis B virus (HBV) infection leads to liver fibrosis, which is a major risk factor in hepatocellular carcinoma (HCC) and an independent risk factor of recurrence after HCC tumor resection. The HBV...

    Authors: Seungyeul Yoo, Wenhui Wang, Qin Wang, M Isabel Fiel, Eunjee Lee, Spiros P. Hiotis and Jun Zhu

    Citation: BMC Medicine 2017 15:214

    Content type: Research article

    Published on:

  7. Direct-acting antivirals (DAAs) have revolutionized chronic hepatitis C (HCV) treatment, but real-world effectiveness among vulnerable populations, including uninsured patients, is lacking. This study was cond...

    Authors: Christina Yek, Carolina de la Flor, John Marshall, Cindy Zoellner, Grace Thompson, Lisa Quirk, Christian Mayorga, Barbara J. Turner, Amit G. Singal and Mamta K. Jain

    Citation: BMC Medicine 2017 15:204

    Content type: Research article

    Published on:

  8. We present two consensus definitions of advanced and late stage liver disease being used as epidemiological tools. These definitions can be applied to assess the morbidity caused by liver diseases in different...

    Authors: Stefan Mauss, Stanislas Pol, Maria Buti, Erika Duffell, Charles Gore, Jeffrey V. Lazarus, Hilje Logtenberg-van der Grient, Jens Lundgren, Antons Mozalevskis, Dorthe Raben, Eberhard Schatz, Stefan Wiktor and Jürgen K. Rockstroh

    Citation: BMC Medicine 2017 15:92

    Content type: Correspondence

    Published on:

  9. Chronic hepatitis B virus (HBV) infection is a global public health issue. Although the disease cannot be cured effectively, disease management has been improved over the past decade. The introduction of poten...

    Authors: Tai-Chung Tseng and Jia-Horng Kao

    Citation: BMC Medicine 2017 15:53

    Content type: Minireview

    Published on:

  10. Non-alcoholic fatty liver disease has emerged a major challenge because of it prevalence, difficulties in diagnosis, complex pathogenesis, and lack of approved therapies. As the burden of hepatitis C abates ov...

    Authors: Brent A. Neuschwander-Tetri

    Citation: BMC Medicine 2017 15:45

    Content type: Minireview

    Published on: